After adjusting for potentially influential factors including age, sex, ethnicity, pre-existing conditions, other medication use, and body mass index, use of GLP-1 receptor agonists was associated with a 37% higher risk of alopecia than use of SGLT-2 inhibitors (6.91 v 5.04 per 1,000 person years) and a 68% higher risk than use of DPP-4 inhibitors (6.53 v 3.89 per 1,000 person years)
For people sensitive to medication side effects or those new to GLP-1 therapy, microdose protocols offer a gentler on-ramp to metabolic benefits
The findings highlight the potential of these formulations to support health and athletic performance, emphasizing their optimized profiles in terms of nutritional density, functional efficacy, and physicochemical stability
The absence of documented interactions reflects a lack of study, not a formal safety determination
Moreover, its novel long-acting profile makes it a uniquely compelling research compound in metabolic science
Effects of L-theanine or caffeine intake on changes in blood pressure under physical and psychological stresses